With the new construct, the anti-FGFR4 CAR-T cells combined with a multi-drug approach targeting the myeloid cells responsible for the immunosuppressive microenvironment showed high tumor elimination capacity in orthotopic mouse models [180]. This evidence concerns the gene FGFR4 and neoplasm.